Artwork

Contenido proporcionado por Clinical Care Options, LLC and Clinical Care Options. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Clinical Care Options, LLC and Clinical Care Options o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !

Current Clinical Practice and NCCN Guidelines for CLL/SLL

31:33
 
Compartir
 

Manage episode 429566073 series 3256997
Contenido proporcionado por Clinical Care Options, LLC and Clinical Care Options. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Clinical Care Options, LLC and Clinical Care Options o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:

  • Prognostic variables when deciding between regimens
  • Role of MRD in CLL
  • Results from the phase II CAPTIVATE trial
  • Choosing among the available covalent BTK inhibitors
  • Preferred partner anti-CD20 antibody in CLL/SLL
  • Role of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLL
  • Use of CAR T-cell therapy in CLL/SLL

Presenters:

Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Jeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Shuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.

Link to full program:
https://bit.ly/3LzA2As

  continue reading

184 episodios

Artwork
iconCompartir
 
Manage episode 429566073 series 3256997
Contenido proporcionado por Clinical Care Options, LLC and Clinical Care Options. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Clinical Care Options, LLC and Clinical Care Options o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:

  • Prognostic variables when deciding between regimens
  • Role of MRD in CLL
  • Results from the phase II CAPTIVATE trial
  • Choosing among the available covalent BTK inhibitors
  • Preferred partner anti-CD20 antibody in CLL/SLL
  • Role of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLL
  • Use of CAR T-cell therapy in CLL/SLL

Presenters:

Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Jeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Shuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.

Link to full program:
https://bit.ly/3LzA2As

  continue reading

184 episodios

Minden epizód

×
 
Loading …

Bienvenido a Player FM!

Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.

 

Guia de referencia rapida